1312 (1312) Fair Value & Analysis

Healthcare · Market cap HK$162M

1 1312 1312 · HK

PriceHK$0.0280

Fair ValueHK$0.0482

Upside+72.0%

Quality50/100

Evidence: Medium Range HK$0.0370 – HK$0.0566

Fair value as of: Jul 2, 2026

From 9 valuation models · updated today

Share price +3.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0220 – HK$0.0400 · fair‑value band HK$0.0370 – HK$0.0566 · the HK$0.0280 price screens below the HK$0.0482 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1312 (1312) currently trades at HK$0.0280, while our model-based Fair Value estimate is HK$0.0482 — implying the stock looks roughly 72.0% undervalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1312 generated revenue of HK$915M at a net margin of -46.8%. Revenue grew 5.2% year over year. It earns a return on equity of -67.1%. Net debt stands at HK$138M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$915M

Revenue growth (YoY) +5.2%

Net margin -46.8%

Return on equity -67.1%

Free cash flow HK$53.2M FY2025

Operating margin -10.2%

More key figures

EPS (TTM) HK$-0.0500

EPS growth (YoY) -87.9%

Net debt HK$138M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1312 reported revenue of HK$915M in FY2025 versus HK$961M in FY2021, a compound −1.2%/yr. Reported net income was −HK$428M in FY2025.

Revenue −1.2%/yr

FY21 HK$961M

FY22 HK$894M

FY23 HK$809M

FY24 HK$898M

FY25 HK$915M

Net income

FY21 −HK$15.0M

FY22 −HK$41.5M

FY23 −HK$28.8M

FY24 −HK$75.5M

FY25 −HK$428M

Is 1312 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1312 (1312) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0482 versus a price of HK$0.0280 — about +72% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1312?

Our model-based fair value for 1312 is HK$0.0482 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0280.

What is the quality score of 1312?

1312 has a Quality Score of 50/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1312 (1312)?

1312 reported trailing-twelve-month revenue of about HK$915M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1312?

The net profit margin of 1312 is about -46.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.